Islet transplantation - The imperative need for continued clinical trials

Nature Clinical Practice Nephrology

Volumn 4, Issue 12, 2008, Pages 662-663

  James Shapiro, A M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CYCLOSPORIN; EXENDIN 4; INSULIN; TACROLIMUS;

CLINICAL TRIAL; DIABETIC PATIENT; GRAFT SURVIVAL; HUMAN; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 56749160150     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0964     Document Type: Short Survey

References (17)

1. Ruggenenti P et al. (2008) Decision time for pancreatic islet-cell transplantation. Lancet 371: 883-884
2. Bliss M (2007) The Discovery of Insulin. Chicago: University of Chicago Press
3. Shapiro AM et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238
4. Shapiro AM et al. (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355: 1318-1330
5. Campbell PM et al. (2007) High risk of sensitization after failed islet transplantation. Am J Transplant 7: 2311-2317
6. Ryan EA et al. (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069
7. Hering BJ et al. (2005) Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293: 830-835
8. Froud T et al. (2008) The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 86: 36-45
9. Gangemi A et al. (2008) Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 8: 1250-1261
10. Ghofaili KA et al. (2007) Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 83: 24-28
11. Suarez-Pinzon WL et al. (2005) Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54: 2596-2601
12. Vincenti F et al. (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781
13. Korsgren O et al. (2008) Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 51: 227-232
14. Emamaullee JA et al. (2008) The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes 57: 1556-1566
15. Cardona K et al. (2007) Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 7: 2260-2268
16. Hering BJ et al. (2006) Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 12: 301-303
17. Kroon E et al. (2008) Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26: 443-452